Use of Warfarin at Discharge among Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation in China

Stroke

Volumn 47, Issue 2, 2016, Pages 464-470

  Wang, Yongjun ^a,b   Yang, Xiaomeng ^a   Li, Zixiao ^a   Zhao, Xingquan ^a   Wang, Chunjuan ^a,b   Liu, Liping ^a,b   Wang, Chunxue ^c   Pan, Yuesong ^d   Li, Hao ^a,b   Wang, David ^e   Hart, Robert G ^f   Wang, Yilong ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b China National Clinical Research   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF ILLINOIS   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; China; Secondary prevention; Stroke; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CHINA; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; STROKE PATIENT; TEACHING HOSPITAL; TREATMENT REFUSAL; AGE; ALCOHOLISM; BLEEDING; CLINICAL PRACTICE; COMPLICATION; DRINKING BEHAVIOR; HEALTH CARE FACILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REGISTER; RISK; RISK FACTOR; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ALCOHOLISM; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHINA; FEMALE; GUIDELINE ADHERENCE; HEALTH FACILITY SIZE; HEMORRHAGE; HOSPITALS, TEACHING; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT DISCHARGE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; REGISTRIES; RISK; RISK FACTORS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT REFUSAL; WARFARIN;

EID: 84969369428     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011833     Document Type: Article

References (31)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/NEJMoa1009638.
6. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.
7. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645.e4. doi: 10.1016/j.amjmed.2009.11.025.
8. Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, et al; China QUEST Study Investigators. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study. Int J Stroke. 2013;8:150-154. doi: 10.1111/j.1747-4949.2011.00716.x.
9. Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. J Stroke Cerebrovasc Dis. 2014;23:1157-1163. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006.
10. Eikelboom JW, Hart RG. Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight. Stroke. 2015;46:5-6. doi: 10.1161/STROKEAHA.114.007486.
11. Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015;46:23-30. doi: 10.1161/STROKEAHA.114.006476.
12. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42:3651-3654. doi: 10.1161/STROKEAHA.111.635755.
13. Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, et al; China National Stroke Registry Investigators. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke. 2011;6:355-361. doi: 10.1111/j.1747-4949.2011.00584.x.
14. Ministry of Health of the People's Republic of China. Annual Report on Health Statistics of China 2010 [in chinese]. Beijing, China: Publishing House of the Peking Union Medical College; 2010.
15. Stroke-1989. Recommendations on Stroke Prevention, Diagnosis, and Therapy. Report of the who task force on stroke and other cerebrovascular disorders. Stroke. 1989;20:1407-1431
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100. doi: 10.1378/chest.10-0134.
19. Lewis WR, Fonarow GC, Grau-Sepulveda MV, Smith EE, Bhatt DL, Hernandez AF, et al. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. Am Heart J. 2011;162:692-699.e2. doi: 10.1016/j.ahj.2011.07.019.
20. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
21. Lin S, Wu B, Hao ZL, Kong FY, Tao WD, Wang DR, et al. Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a Chinese hospital-based stroke study. Cerebrovasc Dis. 2011;31:419-426. doi: 10.1159/000323221.
22. Bo S, Ciccone G, Scaglione L, Taliano C, Piobbici M, Merletti F, et al. Warfarin for non-valvar atrial fibrillation: still underused in the 21st century? Heart. 2003;89:553-554.
23. Wang C, Rao K, Wu S, Liu Q. Health care in China: improvement, challenges, and reform. Chest. 2013;143:524-531. doi: 10.1378/chest.12-1839.
24. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
25. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983. doi: 10.1016/S0140-6736(10)61194-4.
26. Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27:39-50. doi: 10.2165/11319540-000000000-00000.
27. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40:1410-1416. doi: 10.1161/STROKEAHA.108.526988.
28. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther. 2014;36:1135-1144. doi: 10.1016/j.clinthera.2014.07.015.
29. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253.
30. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125-136. doi: 10.1016/j.cjca.2012.01.021.
31. Svendsen ML, Ehlers LH, Ingeman A, Johnsen SP. Higher stroke unit volume associated with improved quality of early stroke care and reduced length of stay. Stroke. 2012;43:3041-3045. doi: 10.1161/STROKEAHA.111.645184.